An interventional study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Alzheimer Disease and Aging, sponsored by Stanford University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Stanford University · Not applicable, Interventional, and Basic science
Funding for this study was not received and so the study was not initiated.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Alzheimer Disease by Stanford University — 2 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · Stanford University.
Among the 10 studies in Alzheimer Disease by Stanford University, this one is the only one that started in 2027, is one of 5 with no phase, and was the 9th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →2 of the 10 studies in Alzheimer Disease by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 50–85
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 18 across the 8 interventional studies, 26 across the 2 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
3 of the studies in Alzheimer Disease by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06052163Stanford UniversityBumetanide in Patients With Alzheimer's Disease | 2026-12-15 |
| NCT07573982Stanford UniversityUltrasonic Debris Clearance to Promote Brain Resilience | 2027-07 |
| NCT06489847Stanford UniversityAn Objective Assessment Tool for Evaluating Functioning in Older Adults | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Alzheimer Disease by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to determine whether non-invasive vagus nerve stimulation enhances memory formation in cognitively healthy older adults and whether the effects of stimulation depend on gut and brain health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive active stimulation during memory encoding of picture-word pairs. Active stimulation will occur during two learning phases of the learning and memory task. The total duration of these two phases will be less than 30 minutes.
Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Participants will receive sham stimulation during memory encoding of picture-word pairs. Sham stimulation will occur during two learning phases of the learning and memory task. The total duration of these two phases will be less than 30 minutes.
Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Non-invasive vagus nerve stimulation will be delivered with a well-validated device. taVNS delivers stimulation on the left ear, with the placement of the stimulating electrode differing between the active and sham conditions. Stimulation will occur during each learning trial (total of 30 trials per phase).
Change in Recognition Memory (d-prime)
d' is a signal-detection sensitivity index-how well participants discriminate old (studied) from new (unstudied) items, independent of response bias. Computed as d' = Z(hit rate) - Z(false-alarm rate) from the old/new recognition memory test. Primary analysis is within-person Δhigh-confidence d' (based on "sure old" responses in the 4-point "sure old", "unsure old", "unsure new", "sure new" scale, Δ = active - sham) and Δoverall d' (based on "sure old" and "unsure old" responses). Main comparison is older vs. young, and within the older group also testing moderation by gut-brain axis measures and interactions with preclinical Alzheimer's disease pathology (pTau217, pTau181, Aβ42:40).
Time frame: post-active vs post-sham stimulation; up to 2 hours of task
Plan to share: Yes — All other data will be made available via Stanford's Digital Repository (SDR) and will be linked with associated analytic code on the Stanford Memory Lab's Github. Additionally, the task and analysis scripts, along with comments explaining the source code and instructions to install and configure software required to run the scripts, will be shared via the website of the Stanford Memory Lab and our repository on GitHub. SDR is accessible to investigators who are not affiliated with Stanford University and does not require data to be associated with a publication prior to being accepted by the repository. This data archiving approach ensures that the broader scientific community will have long-term access to all data and analysis code.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: The data will be made available upon publication of corresponding results or at the end of the award period, whichever is sooner. They will remain available indefinitely or until the end-of-life of the corresponding data-hosting platforms, if no suitable alternative can be identified.
Access criteria: De-identified MRI and other components of the dataset will be findable and identifiable via persistent Stanford Digital Repository (SDR) URLs. These links will be embedded in published preprints and manuscripts, as well as with direct links on the Stanford Memory Lab's webpage. The SDR does not require data to be associated with a publication to be accepted by the repository. Processed microbiome data tables and metadata will be findable and identifiable through GEO accession numbers. The raw sequencing data will be findable and identifiable through SRA accession numbers. Access to de-identified data will not be controlled (i.e., once publicly available, anyone can access the de-identified data).
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Jul 2028, 17 months later.
How these figures are worked out, and which studies are left out of them.
Funding for this study was not received and so the study was not initiated.
Funding for this study was not received and so the study was not initiated.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.